Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
Amylyx Pharmaceuticals announced two poster presentations at the Endocrine Society’s ENDO 2026 meeting in Chicago, scheduled for June 14-15, 2026. The posters cover the burden of post-bariatric hypoglycemia (PBH) and participant-centric design considerations for the pivotal Phase 3 LUCIDITY trial of avexitide. Avexitide is a first-in-class GLP-1 receptor antagonist with Breakthrough Therapy Designation for PBH; the LUCIDITY trial involves 78 participants across 21 U.S.
Key figures
- Drug Name
- avexitide
- Phase Of Trial
- Phase 3
- Dosage
- 90 mg
- Trial sites
- 21
- Prevalence us
- 160,000
- Treatment duration
- 16 weeks
- Trial participants
- 78
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.